@precogonc.bsky.socialShout out to @OSUCCC_James & for enrolling its first patient in PrE0510, our phase 2 #ClinicalTrial exploring the optimal dose of ivonescimab with carboplatin and etoposide in extensive-stage #SmallCellLungCancer (#SCLC). Learn more: bit.ly/PrE0510
@precogonc.bsky.socialGreat work to @luriecancer.bsky.social for enrolling its first patient in PrE0510, our phase 2 #ClinicalTrial exploring the optimal dose of ivonescimab with carboplatin and etoposide in extensive-stage #SmallCellLungCancer (#SCLC). Learn more: bit.ly/PrE0510
@4040rec.bsky.social
@gmj-georgia.bsky.socialNature Medicine has published an author correction for the ABBV-706 phase 1 trial, a SEZ6-targeting antibody-drug conjugate being tested in a… #ABBV706 #Antibodydrugconjugate #Phase1trial #Precisiononcology #Smallcelllungcancer #ABBV706 #Antibodydrugconjugate #Phase1trial #Precisiononcology #Sm…
@pharmaphorum.bsky.social#Amgen's fast-growing cancer #immunotherapy #Imdelltra could move into the first-line setting in #smallcelllungcancer (SCLC), after delivering as a #dualregimen with AstraZeneca's Imfinzi in the DeLLphi-305 study.
@gmj-georgia.bsky.socialNature Medicine has published an author correction for the ABBV-706 phase 1 trial, a SEZ6-targeting antibody-drug conjugate being tested in a… #ABBV706 #Antibodydrugconjugate #Phase1trial #Precisiononcology #Smallcelllungcancer #ABBV706 #Antibodydrugconjugate #Phase1trial #Precisiononcology #Sm…